Mergers & Acquisitions

Greenhill's M&A practice includes some of the most experienced professionals in the industry. Drawing on that experience, we are active across the full range of M&A advisory roles:

Sell-side Advisory

Leveraging our independence and lack of conflicts, we have a strong track record in sell side advisory roles. Acting for target companies, special board committees or selling shareholders, we can operate at the heart of any process, assist in negotiations and give impartial and objective advice about the merits of bids received.

Buy-side Advisory

We have a strong record of successful buy side advisory assignments in relation to public or private target companies and are able to advise interested buyers on attractive targets through our global network of relationships.

Merger Advisory

Greenhill is well qualified to assist clients on merger transactions given the long experience of its partners and professionals, an assurance of total discretion and a lack of conflicting interests. Greenhill has a number of sizeable mergers in its list of completed transactions both in the US and internationally.

Special Advisory

Various advisory work that we undertake does not fit a conventional ‘transaction’ definition. Examples include our work advising the Australian National Rugby League Commission on the sale of television broadcast rights and work for the global partnership of Arthur Andersen in the immediate aftermath of the cases that followed the collapse of Enron. We believe that Greenhill’s independence, experience, expertise and discretion positions us well for special advisory assignments.

Cross-border Advisory

Greenhill’s network of international offices and our ‘single Firm’ operating model allow us to offer clients a seamless cross-border advisory service with a truly global perspective.

Recent Transactions

並べ替え

2023 年 01 月 23 日
発表済
$200 million
United Kingdom flag
被買収企業: 

Clinigen Ltd’s Proleukin

United States flag
買収企業: 
Iovance Biotherapeutics

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies

2023 年 01 月 09 日
発表済
Undisclosed
Switzerland flag
被買収企業: 

Schurter

Switzerland flag
買収企業: 
Capvis

Advising Capvis, a leading European mid-market investor, on the acquisition of Schurter, a global provider of components for circuit protection, connectors, switches and EMC products

2022 年 12 月 30 日
$153 million
United States flag
被買収企業: 

Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products

Australia flag
買収企業: 
Mayne Pharma

Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma

2022 年 12 月 28 日
発表済
Undisclosed
Japan flag
被買収企業: 

エーザイ物流

Japan flag
買収企業: 
安田倉庫

国内製薬会社大手エーザイのセルサイド・アドバイザー(単独)として、国内総合物流サービス大手安田倉庫に対する、国内医療用医薬品物流サービス大手エーザイ物流(エーザイ100%子会社)の売却をサポート

2022 年 12 月 23 日
発表済
Undisclosed
Germany flag
被買収企業: 

Exyte Management GmbH

United States flag
買収企業: 
BDT Capital Partners LLC

Advising Stumpf Capital and Georg Stumpf on the sale of a minority interest in its wholly-owned company, Exyte, a global leader in the design, engineering and delivery of high-tech facilities, to funds affiliated with BDT Capital Partners

ページ

すべて表示